Profile data is unavailable for this security.
About the company
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
- Revenue in USD (TTM)59.85m
- Net income in USD1.60m
- Incorporated1993
- Employees68.00
- LocationCompugen LtdAzrieli Center, 26 Harokmim St., Bldg DHOLON 5885849IsraelISR
- Phone+972 37658585
- Fax+972 37658555
- Websitehttps://cgen.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioLine RX Ltd | 42.41m | -178.84m | 102.63m | 79.00 | -- | 1.69 | -- | 2.42 | -0.185 | -0.185 | 0.0422 | 0.0437 | 0.1939 | -- | 6.40 | 536,838.10 | -81.75 | -52.74 | -127.94 | -65.43 | 55.84 | -- | -421.69 | -3,501.79 | 1.05 | -519.43 | 0.4642 | -- | -- | -- | -142.93 | -- | -50.72 | -- |
| DNA Group TR Ltd | 306.00k | 15.05m | 109.25m | 14.00 | 7.08 | 1.08 | -- | 357.01 | 0.1222 | 0.1222 | 0.0025 | 0.7981 | 0.0033 | -- | 1.44 | 21,857.14 | 16.35 | -23.54 | 16.48 | -26.27 | -- | -- | 4,918.63 | -7,406.24 | -- | -- | 0.00 | -- | -45.36 | -- | 95.00 | -- | -- | -- |
| Bonus Biogroup Ltd | 0.00 | -29.19m | 130.81m | 58.00 | -- | 8.27 | -- | -- | -0.0718 | -0.0718 | 0.00 | 0.0132 | 0.00 | -- | -- | 0.00 | -64.14 | -76.10 | -74.97 | -97.19 | -- | -- | -- | -- | -- | -- | 0.4106 | -- | -- | -- | 26.29 | -- | 19.30 | -- |
| Compugen Ltd | 217.79m | 5.82m | 459.39m | 68.00 | 73.33 | 2.08 | -- | 2.11 | 0.0698 | 0.0698 | 2.44 | 2.46 | 0.6263 | -- | 24.50 | 3,202,786.00 | 1.67 | -28.41 | 2.09 | -32.57 | 84.53 | 92.40 | 2.67 | -293.48 | -- | -- | -- | -- | 346.12 | 13.45 | 44.34 | -- | 1.71 | -- |
